Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Current Investments (2019 - 2026)

C4 Therapeutics has reported Cash & Current Investments over the past 8 years, most recently at $235.7 million for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 9.57% year-over-year to $235.7 million; the TTM value through Mar 2026 reached $235.7 million, up 9.57%, while the annual FY2025 figure was $248.5 million, 1.48% up from the prior year.
  • Cash & Current Investments for Q1 2026 was $235.7 million at C4 Therapeutics, down from $248.5 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $313.7 million in Q3 2022 and troughed at $191.9 million in Q3 2025.
  • A 5-year average of $254.4 million and a median of $255.6 million in 2024 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: crashed 33.94% in 2022 and later grew 18.04% in 2024.
  • Year by year, Cash & Current Investments stood at $276.2 million in 2022, then decreased by 8.14% to $253.7 million in 2023, then decreased by 3.46% to $244.9 million in 2024, then increased by 1.48% to $248.5 million in 2025, then dropped by 5.18% to $235.7 million in 2026.
  • Business Quant data shows Cash & Current Investments for CCCC at $235.7 million in Q1 2026, $248.5 million in Q4 2025, and $191.9 million in Q3 2025.